Short answer
AVITA Medical, Inc. (RCEL) filed an 8-K current report with the SEC on June 8, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Stockholder approval enabled June 5 warrant issuance to Perceptive, completing equity consideration tied to the credit facility.
AVITA Medical, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Stockholder approval enabled June 5 warrant issuance to Perceptive, completing equity consideration tied to the credit facility
- Initial warrant covers 500,000 shares at $3.4019 exercise price, creating potential dilution
- Additional 150,000 shares vest if AVITA draws the $10 million commitment by March 31, 2027
- Credit facility totals up to $60 million, with $50 million initially available and $10 million contingent on net revenue requirements
- Warrant shares registered under Form S-3, supporting potential future resale liquidity for Perceptive
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AVITA Medical, Inc. 8-K filings
Get the next RCEL 8-K as it lands
Follow RCEL for push alerts, or ask the research agent what this filing means.